Hetero completed the acquisition of a manufacturing plant in Telangana from Johnson & Johnson for $16m.

Hetero, a pharmaceuticals firm, completed the acquisition of a manufacturing plant in Telangana from Johnson & Johnson, a holding company, which engages in the research and development, manufacture and sale of products in the health care field, for $16m. "We are committed to an investment upwards of approximately Rs 600 crore to upgrade and enhance existing facilities at the site and expand manufacturing of our global biologics and sterile pharmaceutical products," Vamsi Krishna Bandi, Hetero Managing Director.